carna biosciences inc (4572) Details

Carna Biosciences, Inc. engages in the provision of drug discovery supporting products and services; and discovery and development of drugs. Its drug discovery supporting products and services include kinase proteins; biotinylated kinases that could be used for the study of kinase-molecule interactions; profiling services; reverse phase protein array cell signaling analysis service, which could be used to determine whether signaling pathways were affected inside a cell by a kinase inhibitor; live-cell kinase assays that offer tyrosine kinase profiling and screening services; and ClariCELL kinase cell-based assay services. The company’s drug discovery supporting products and services also comprise assay development services, such as kinase genetic cloning, kinase protein production, substrate search optimization, and assay optimization services; crystallography service for various kinases; and protein substrates that could be used for kinase assays. It also identifies and develops medicines primarily for the treatment of cancer and anti-inflammatory diseases using its QuickScout, a kinase drug discovery platform. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.

carna biosciences inc (4572) Top Compensated Officers